Vistusertib (AZD2014)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Vistusertib (AZD2014), covering 2024-09-20 to 2024-09-20. Get the full timeline:
Most recent: Clinical Trial Update: Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) [Phase 2]